CA
NZ
UK
AU
IND
US
The company posted a net loss of $20.2 million for the quarter, after incurring $16.4 million inResearch and Developmentcosts and $5.8 million in general and administrative expenses. ThisLiquiditycushion and ongoing trial activity suggest the firm can sustain its development timeline without immediate fundraising pressure.
Indivior Pharmaceuticals (Nasdaq: INDV) posted Q2 earnings per share of $0.96, topping the $0.67 consensus estimate. The earnings beat came alongside a $175 million share repurchase program, a sum that represents roughly 4% of the company’s $4.9 billion market value. The combination of an …
Indivior Pharmaceuticals (Nasdaq: INDV) announced it will merge with Supernus Pharmaceuticals, converting each Supernus share into 1.5401 Indivior shares. The deal will leave Indivior owners with about 56.5% of the combined firm, while a $1 billion special cash dividend will be paid to shareholders …
Integer Holdings Corp (NYSE: ITGR) experienced a 2.6% sales decline, totaling $464 million for the second quarter ending July 3, 2026. This drop is particularly notable against the backdrop of a consensus estimate of $1.21 EPS for the previous quarter, indicating operational headwinds. The …
Krystal Biotech, Inc. (Nasdaq: KRYS) reported financial results for the second quarter ending June 30, 2026, highlighting $119.2 million in global revenue, marking a 24% increase compared to the same period last year. This revenue surpassed the consensus estimate of $1.69Earnings Per Share(EPS) with …
Ocular Therapeutix, Inc. (NASDAQ: OCUL) reported a second-quarter 2026 loss of $-0.40 per share, falling short of the $-0.32 consensus estimate. The company’s marketCapitalizationstands at approximately $1.8 billion, reflecting investor sentiment amid its evolving product pipeline and market dynamics. In comparison, Ocular previously reported …
AstraZeneca and Bristol Myers Squibb are in the midst of merger discussions that value the combined entity at $400bn, a figure that would rank the transaction among the largest ever seen in the pharmaceutical sector. The news sparked an immediate divergence inEquitymarkets, with AstraZeneca’s …
Autolus Therapeutics plc (Nasdaq: AUTL) has boosted its 2026 net product revenue guidance for AUCATZYL® to between $140 million and $150 million, a notable increase from its previous estimate of $120 million to $135 million. This adjustment signals confidence in the biopharmaceutical company's sales …
VistaGen Therapeutics has broadened its leadership by appointing a new board director committed to advancing neuroscience drug development. This strategic addition reflects the company's focus on enriching its team with experienced professionals, particularly in an area of high relevance to its product pipeline. The …
Werewolf Therapeutics, Inc. (Nasdaq: HOWL) posted a $3.7 million net profit for the quarter ended June 30, 2026, a sharpReversalfrom the $18.0 million loss recorded a year earlier. TheEarningsbeat the consensus estimate of $‑0.29 per share, delivering an EPS of $‑0.28. Cash and cash …
Please wait processing your request...